Acadia Pharmaceuticals Inc (ACAD) · Oct 23, 2026 · Exec change
R&D transition — Consulting through December 31, 2026; replacement not yet named
Acadia’s executive change is now effective: its R&D chief leaves the employee role but remains a consultant while a replacement search continues.
Acadia is a commercial neuroscience and rare-disease company built around Nuplazid and Daybue, while trying to advance remlifanserin and other pipeline programs into later-stage development. Its R&D leadership is especially relevant because remlifanserin is the lead growth program and the company is moving from clinical readout toward Phase 3 execution.
The departure is now operational, not newly announced. Elizabeth Thompson no longer serves as an employee or Head of R&D as of October 23, but Acadia had already disclosed her planned retirement on April 30 and said she would remain involved through the transition. 〔0〕 The filing therefore confirms a scheduled change rather than introducing a surprise.
The consultant arrangement reduces near-term disruption but does not solve the leadership gap. Thompson intends to provide limited consulting services through December 31, while Acadia is still identifying her replacement. 〔1〕 That provides a short continuity bridge, but the company has not named the person who will own R&D beyond year-end.
Bottom line: This is a priced-in executive transition with a temporary continuity measure, not a change to Acadia’s clinical strategy or pipeline. It matters mainly because the replacement search remains unfinished as the company advances its next-stage development work.
Appointment of replacement Head of R&D
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!